Available online www.ijpras.com

International Journal of Pharmaceutical Research & Allied Sciences, 2025, 14(3):93-102
https://doi.org/10.51847/Hjr7ekB1hr

Original Article

ISSN : 2277-3657
CODEN(USA) : IJPRPM

Engineering the Therapeutic Cell Factory to Reconcile Product Yield, Molecular Quality, Biological Function, and Manufacturing Robustness

Santiago Morales[1]*, Laura Rojas[2], Camila Vega[1], Diego Molina[3]

[1] *Department of Therapeutic Cell Factory Engineering, Faculty of Pharmacy, University of Buenos Aires, Buenos Aires, Argentina.*
[2] *Department of Product Yield and Molecular Quality, Faculty of Pharmacy, Pontifical Catholic University of Chile, Santiago, Chile.*
[3] *Department of Manufacturing Robustness and Function, Faculty of Pharmacy, National University of La Plata, La Plata, Argentina.*

***Email:** santiago.morales@agro.uba.ar*

ABSTRACT

Therapeutic-protein manufacturing is often optimized through productivity-centered objectives, although increased product formation can alter metabolic allocation, folding demand, molecular heterogeneity, biological activity, cellular stability, and process sensitivity. This article proposes the Therapeutic Cell-Factory Reconciliation Architecture, an original non-empirical framework that organizes these interdependencies without reducing performance to titer or a single composite score. The architecture represents the therapeutic cell factory through coupled host, resource-allocation, expression and secretory-processing, process, product-attribute, stability, and control states. Yield, molecular quality, biological function, and manufacturing robustness are treated as non-substitutable objectives whose relationships depend on host, molecule, culture phase, operating mode, process history, and the active constraint. Process coupling is incorporated by tracing how environmental conditions influence intracellular allocation, product processing, extracellular integrity, population stability, and disturbance response. Design rules distinguish persistent constraints suited to static engineering from phase-dependent constraints that may justify dynamic intervention. Measurement, state estimation, and an uncertainty-aware world model are positioned as hypothesis-organizing components rather than validated decision systems. Validation requires orthogonal cellular, process, molecular, functional, longitudinal, and perturbational evidence, prospective testing, and explicit transfer boundaries. The contribution is a platform architecture that connects cell engineering to product-centered manufacturing consequences while preserving distinctions among plausibility, evidence, prediction, intervention, and readiness. It is not a validated model, qualified control strategy, regulatory standard, or deployment-ready system.

Key words: *Pharmaceutical biotechnology, Biomanufacturing, Cell factory, Bioprocess, Biologic developability, Synthetic biology*

Received: 09 May 2025; **Revised:** 28 August 2025; **Accepted:** 06 September 2025

INTRODUCTION

Therapeutic biologics are produced through coordinated cell-line development, host engineering, culture optimization, process monitoring, and product characterization. Mammalian platforms support diverse recombinant medicines, yet continued improvement increasingly requires integration across cell, process, and

product domains [1–3]. The therapeutic cell factory should therefore be understood as a changing biological system whose internal state influences the attributes of the recovered product. This view also shifts engineering attention from isolated component performance toward the continuity of evidence linking a designed cellular change to a defensible pharmaceutical outcome.

Productivity remains attractive because titer, specific productivity, duration, and recovered quantity are measurable. These indicators are necessary but incomplete: they do not establish correct folding, appropriate modification, acceptable heterogeneity, resistance to degradation, biological activity, or persistence under disturbance. Product quantity is consequently one dimension of manufacturing performance rather than a surrogate for complete pharmaceutical acceptability [1]. The same caution applies to any single analytical or computational proxy that is convenient to measure but only partially represents the intended product or manufacturing objective.

Genome engineering, synthetic biology, multi-omics, metabolic modeling, process analytics, and forecasting have expanded what can be observed and manipulated. The unresolved problem is not simply a shortage of tools, but the lack of an architecture connecting interventions to distinct product consequences while retaining uncertainty, instability, and transfer limits. A systems description alone does not define objectives, constraints, control points, or validation endpoints [3].

This Original Biotechnology Platform Architecture Article proposes the Therapeutic Cell-Factory Reconciliation Architecture as a conceptual synthesis. It integrates host state, resource allocation, secretory processing, process history, product attributes, cellular drift, and manufacturing robustness. Its purpose is to define the architecture, derive testable design rules, and specify validation requirements without claiming empirical validation, regulatory endorsement, or universal applicability.

The Conflict between productivity and product quality

The conflict does not arise because productivity and quality are necessarily opposed. It arises because interventions intended to increase product formation can modify the conditions under which molecules are synthesized, folded, modified, secreted, and maintained. Culture conditions and growth-coupled production can affect titer and product attributes simultaneously, so productivity cannot be treated as independent of quality [4–6].

A trade-off must be distinguished from a shared response to an upstream variable. Culture pH can alter growth, antibody titer, intracellular pathways, and product-quality characteristics in the same system [5]. A quality change accompanying a productivity change may therefore arise from metabolism, enzyme activity, transport, culture duration, or extracellular exposure rather than productivity itself.

Growth-production decoupling illustrates both opportunity and limitation. Separating proliferation from recombinant production may redirect resources and extend the productive phase [6]. However, decoupling does not itself prove improved folding, modification, secretion, stability, function, or robustness. A high-producing state may still accumulate stress, heterogeneity, or population drift. Evaluation should therefore compare the complete product and cellular profile before and after decoupling, including whether the intervention changes culture longevity, stress adaptation, or the distribution of productive states rather than only the population mean.

The conflict is best interpreted as a constrained allocation and capacity problem. Recombinant production draws on transcriptional, translational, energetic, redox, membrane, folding, trafficking, and modification resources that also support cellular maintenance. When capacities become limiting, greater production demand may alter cell or product states. The evidence supports conditional coupling, not a universal rule that more productivity compromises quality. Alternative explanations must remain visible because similar product profiles may arise through different combinations of metabolic limitation, processing capacity, exposure history, and analytical sensitivity.

Proposed therapeutic cell-factory architecture

The proposed architecture defines a therapeutic cell factory as the coupled host, intracellular machinery, extracellular environment, measurement system, and intervention logic through which a therapeutic product is generated. A cell line is one component rather than the complete platform, and process history is biologically active because it can reshape cellular state and product exposure [3].

Three capabilities make this architecture increasingly feasible: controlled genomic construction, dynamic intervention, and higher-resolution state measurement. Targeted integration can reduce uncertainty from uncontrolled transgene placement; dynamic synthetic-biology strategies can support phase-dependent control; and

sub-omics can reveal variation hidden by bulk measurements [7–9]. Together they enable more precise hypotheses, but do not establish acceptable product performance. Their integration is valuable only when the measurements resolve states relevant to the intended intervention and when downstream assays are capable of detecting both anticipated benefits and unintended pharmaceutical consequences.

Figure 1 presents the original conceptual synthesis for therapeutic cell-factory architecture linking cell state to product attributes, showing how the article's principal components, evidence relationships, uncertainties, and decision boundaries are connected.



Figure 1. Therapeutic Cell-Factory Architecture Linking Cell State to Product Attributes

The architecture contains seven connected but non-equivalent states. Host state covers genomic and epigenetic configuration, karyotype, clonal composition, growth, and stress. Resource state covers nutrients, energy, redox, lipids, nucleotide sugars, and translation. Secretory state covers expression, folding, modification, trafficking, secretion, and degradation. Process, product, stability, and control states complete the structure [8].

A defining rule is non-substitution. Higher yield cannot compensate for unacceptable degradation, altered glycosylation, impaired function, or instability. Conversely, acceptable molecular attributes do not prove productivity, scalability, or robustness. Biological function remains separate because structural measurements may not capture every product-specific mechanism, while robustness concerns the combined host-product-process system under specified disturbances. The architecture therefore favors constrained multiobjective reasoning over an aggregate score that could conceal failure in one indispensable dimension.

The architecture also proposes a world model representing relationships among its states. It is not automatically a digital twin. High-resolution omics can improve state description, but observational detail does not establish causal control [9]. Usefulness requires evaluation of assumptions, identifiability, prediction error, uncertainty calibration, operating limits, and prospective performance.

Host-cell metabolism and resource allocation

Host metabolism supplies precursors, energy, reducing power, membranes, and intermediates needed for growth, maintenance, recombinant synthesis, modification, and secretion. These demands compete within a changing environment and can generate inhibitory byproducts. Targeted metabolic engineering has shown that defined pathways contributing to growth inhibitors can be altered in fed-batch CHO culture [10].

Resource allocation cannot be reduced to extracellular nutrient concentration. A nutrient may be abundant yet poorly transported, diverted, or unavailable when required. Genome-scale forecasting can guide essential amino-acid control [11]. Within the architecture, however, a model-guided recommendation remains conditional on model structure, product representation, measurements, parameterization, and agreement between modeled and actual states.

The metabolic layer must represent the cost of processing the specific therapeutic molecule. Genome-scale reconstruction of the mammalian secretory pathway indicates that secretion imposes protein-dependent energetic and machinery demands [12]. Two lines with similar central metabolism may therefore encounter different folding, modification, trafficking, or vesicular constraints when producing different molecular formats.

The proposed allocation mechanism treats growth, maintenance, stress adaptation, recombinant synthesis, folding, modification, trafficking, secretion, and byproduct management as competing or conditionally cooperative demands. It does not assume one universal limiting resource. Validation requires paired extracellular, intracellular, secretory, molecular, and functional measurements across relevant culture phases. Time resolution is especially important because a resource constraint may appear transient in bulk data while producing persistent effects on later product processing or population composition.

Expression, folding, modification, and secretion

Recombinant production is often aggregated under "expression," although transcription and translation begin a longer pathway. A therapeutic protein must fold, pass quality control, undergo relevant modification, traffic intracellularly, and enter the extracellular environment without consequential degradation. Secretory-pathway engineering shows that pathway-associated targets can alter recombinant production in CHO cells [13].

Organelle capacity illustrates why output cannot be separated from cellular architecture. Engineering lipid metabolism can expand the endoplasmic reticulum and enhance recombinant production [14]. Increased organelle volume, however, is not direct evidence of improved quality. Folding, modification, trafficking, and quality-control functions must expand coherently, and the secreted molecule must remain acceptable.

Host comparison shows that difficult-to-express proteins do not encounter one universal bottleneck. Differences between HEK293 and CHO secretory pathways can identify interventions that rescue production for particular molecules [15]. Successful engineering is therefore conditional on both host and product, and gross productivity cannot reveal the molecular specificity determining whether an intervention is appropriate.

The architecture separates transcription, translation, folding, modification, trafficking, secretion, and extracellular stability. Increased transcript does not prove translation; intracellular protein does not prove correct folding; secretion does not prove acceptable modification; and extracellular concentration does not prove function. Each intervention must be assigned to an expected stage and evaluated through downstream evidence. This staged logic also allows negative findings to be interpreted more precisely, separating failure to alter the intended cellular mechanism from successful mechanistic action that does not translate into an acceptable product state.

Product-quality and functional attributes

Product quality is generated dynamically during culture rather than inspected into the product after harvest. Glycosylation can change as metabolic, transcriptional, nutrient, and process states evolve [16]. Harvested material therefore reflects accumulated cellular and extracellular history. The architecture represents quality as a time-integrated output rather than a property determined solely by the expression construct.

Host-derived impurities create another link between cell engineering and integrity. Specific host-cell proteins may remain active and contribute to degradation. Targeted CHO engineering can reduce defined host-cell protein activities and mitigate particular degradation mechanisms [17]. This supports mechanism-specific impurity control, but not indiscriminate elimination of host proteins.

Multi-attribute methods can coordinate monitoring of several molecular properties [18]. Their value lies in direct evidence rather than process proxies, but their scope remains bounded by analytes, detection limits, sample preparation, standards, and validation. Molecular characterization does not automatically establish biological function, clinical equivalence, or regulatory acceptability.

Biological function therefore remains distinct from molecular quality. Structural attributes may be mechanistically linked to function, but the relationship varies by format and mechanism. Product-specific functional assays are required where structural proxies are insufficient. Assay selection should reflect the intended biological mechanism and should be accompanied by controls that distinguish genuine loss of activity from matrix effects, analytical variability, or inappropriate representation of the product's mode of action. **Table 1** organizes the evidence, constructs, relationships, uncertainties, and boundary conditions required for definitions, components, relationships, and intended uses in engineering the therapeutic cell factory to reconcile product yield, molecular quality.

Table 1. Definitions, components, relationships, and intended uses in Engineering the Therapeutic Cell Factory to Reconcile Product Yield, Molecular Quality.

Component or scientific dimension	Problem addressed	Inputs or determinants	Proposed mechanism or relationship	Expected contribution	Evidence required	Failure or uncertainty risk	Boundary statement
Therapeutic cell factory	Fragmented engineering	Host, construct, process, measurement	Proposed coupling of producer, process history, product state, and intervention	Product-centered organization	Integrated host-process-product evidence [3]	Missing modality-specific mechanisms	Organizing construct, not validated platform
Host state	Uncontrolled cellular context	Integration, epigenetics, karyotype, clonality, stress	Shapes expression, stability, and demand	Better attribution	Genomic, single-cell, phenotypic evidence [7]	Hidden subpopulations	Host characterization does not establish product acceptability
Resource allocation	Competition among demands	Nutrients, energy, redox, lipids, amino acids	Proposed allocation among growth, maintenance, production, adaptation	Identifies constraints	Perturbation and intracellular evidence [10]	Compensation, non-identifiability	Not transferable without testing
Secretory processing	"Expression" hides stages	Folding, ER, modification, trafficking	Product-dependent stage constraints	Locates bottlenecks	Stage-specific evidence [13]	More secretion with poor quality	Quantity does not establish function
Process history	Culture conditions treated as external	Feed, pH, temperature, gases, duration, scale	Process changes cell state and product exposure	Links control to outcomes	Longitudinal evidence [5]	Confounding	Association is not causation
Product attributes	Proxies replace direct evidence	Yield, glycosylation, impurities, stability, potency	Four non-substitutable objectives	Direct assessment	Qualified analytics and functional assays [16]	Incomplete coverage	Analytical similarity is not clinical equivalence
Stability and robustness	Mean titer masks drift	Population state, time, mode, perturbation	Proposed persistence of acceptable distributions	Detects deterioration	Longitudinal and disturbance evidence [19]	Rare subpopulations	Claims are bounded to tested domains
World model and control	Prediction confused with readiness	Sensors, estimators, models, intervention rules	Proposed uncertainty-aware link from state to action	Organizes experiments	Prospective testing [20]	Overfitting, domain shift	Not a digital twin by default

Cellular burden, instability, and evolutionary drift

Cellular burden can arise from transcription, translation, folding, modification, secretion, stress management, and maintenance. These demands may alter population composition before mean titer declines. Single-cell karyotype

analysis can reveal genomic instability hidden by population averages [19]. Stability should therefore be considered distributionally rather than only through bulk productivity.

Clonal derivation does not eliminate later heterogeneity. Single-cell transcriptomics has traced production instability within a clonally derived CHO line and identified subpopulations associated with changing production behavior [21]. A culture may retain an acceptable mean while productive, stressed, or nonproductive states are shifting.

Instability is multicausal. Genomic change, epigenetic regulation, silencing, copy-number variation, altered selection pressure, culture adaptation, and process conditions may contribute through different pathways [22]. Not every temporal change is evolutionary drift; reversible physiology, nutrient change, analytical variation, or disturbance may produce similar observations.

The stability layer therefore includes genetic, epigenetic, phenotypic, production, product-quality, and population-composition stability. Stable copy number does not prove stable expression, and stable expression does not prove stable quality. The relevant duration must match the intended operating mode and manufacturing claim. Stability evaluation should also consider whether rare states possess a selective advantage, because a small subpopulation may be operationally unimportant at one time point yet become dominant during extended culture or repeated expansion.

Process coupling and manufacturing robustness

Robustness requires a specified disturbance domain. A meaningful claim must define disturbance type, magnitude, duration, response variables, acceptable region, measurement uncertainty, and host-product-process context [23]. Similar performance under nominally identical conditions may demonstrate reproducibility, but not resistance to relevant variation. Robustness evidence should include deliberately selected disturbances that represent plausible sources of manufacturing variation and should distinguish recovery, compensation, and irreversible state change.

Operating mode changes the biological and manufacturing context. Perfusion alters cell retention, residence time, nutrient and byproduct exposure, control demands, duration, and opportunities for drift [24]. A line performing consistently in a shorter fed-batch process may behave differently under prolonged retention, while product stability may depend on exposure history.

Disturbances can propagate through several paths. Changes in pH, temperature, gas transfer, osmolality, feed timing, or hydrodynamics may alter metabolism, stress, secretion, population composition, and extracellular integrity. Consequences may be delayed, requiring time-resolved process, cellular, molecular, functional, and stability measurements. Scale-down studies are informative only when they reproduce the disturbance mechanisms and exposure histories that matter at manufacturing scale rather than merely matching average operating values.

Robustness must also be distinguished from controllability. A sensitive process may remain controllable through timely intervention, whereas an apparently insensitive process may conceal unmeasured change**. Table 2** organizes the evidence, constructs, relationships, uncertainties, and boundary conditions required for testable propositions, evidence requirements, and validation criteria for engineering the therapeutic cell factory to reconcile product yield, molecular quality.

Table 2. Testable propositions, evidence requirements, and validation criteria for Engineering the Therapeutic Cell Factory to Reconcile Product Yield, Molecular Quality.

Architecture layer or process stage	Core function	Information or material flow	Interaction with other components	Validation criterion	Potential failure mode	Human or experimental responsibility	Readiness boundary
Host construction	Establish starting state	Construct to genomic context	Shapes expression and stability	Verify identity, context, phenotype, product consistency [7]	Silencing or drift	Define and assay host state	Clone is not validated platform
Resource allocation	Supply production and adaptation	Nutrients to flux and precursors	Constrains secretion and stress	Perturb resource and reproduce predicted effects [11]	Compensation	Pair models with intracellular evidence	Not a universal feeding rule

Folding and secretion	Produce processed molecule	Polypeptide through ER and trafficking	Couples resource state to quality	Demonstrate mechanism and preserved attributes [15]	Misfolding or degradation	Use structural and functional assays	Secretion increase is not product suitability
Product assessment	Characterize recovered material	Product to molecular and functional evidence	Tests upstream consequences	Use qualified attribute and functional methods [18]	Missing consequential attribute	Justify assay relevance	Analytical similarity is not clinical equivalence
Stability	Preserve productive distributions	Population state through time	Alters yield, quality, robustness	Demonstrate longitudinal persistence [21]	Expanding altered subpopulation	Separate adaptation from drift	Short-term clonality is insufficient
Process management	Maintain environment	Feed, gases, heat, mixing, time	Acts across cell and product states	Reproduce performance across defined variation [23]	Sensor bias or gradients	Define disturbances and delayed effects	Nominal control is not robustness
World model	Represent state relationships	Data and knowledge to predictions	Supports intervention selection	Verify structure, uncertainty, prospective performance [20]	Overfitting or domain shift	State intended use	Prediction is not digital-twin readiness
Transfer evaluation	Test reuse in a new domain	Knowledge across hosts, products, modes, scales	Identifies invariants and recalibration	Demonstrate external performance [25]	Hidden domain shift	Predefine transfer claim	Portability remains conceptual until tested

Design rules and control points

The first design rule is to distinguish biological representation from a validated digital manufacturing system. Computational approaches can support a digital bioprocess replica by linking mechanistic knowledge, measurements, and simulation [20]. The proposed world model is a structured hypothesis about state relationships, not a digital twin merely because it reproduces historical trajectories.

The second rule is to match prediction to intended use. Data-driven models can forecast multistep mammalian-culture profiles [26]. Retrospective interpretation, anomaly detection, intervention recommendation, and quality-risk prediction require different evidence. Prospective error, horizon, drift, uncertainty, missing-data sensitivity, and failure detection must be evaluated in the intended domain.

The third rule is to match intervention timing to constraint persistence. Stable structural limitations may justify constitutive engineering, whereas phase-specific limitations may favor inducible control. Dynamic CHO engineering provides a basis for state-dependent programs [8], but adds sensing, circuit, timing, stability, and failure-mode requirements.

The fourth rule is to require downstream evidence proportional to intervention reach. A nutrient change should be evaluated beyond concentration, a metabolic edit beyond growth, a secretory edit beyond quantity, and a model-based action beyond prediction. Unexpected outcomes should be treated as evidence about missing structure rather than dismissed as noise [26]. Control-point selection should therefore include an explicit alternative-mechanism analysis, identifying which observations would contradict the preferred explanation and which measurements would discriminate among plausible pathways.

Validation criteria and platform transferability

Computational validation should extend beyond agreement with observed culture profiles. CHO genome-scale models can organize metabolic knowledge for digital biomanufacturing, but utility depends on biological representation, assumptions, data quality, uncertainty, and intended use [27]. Validation should test structure, identifiability, perturbational prediction, uncertainty calibration, and pharmaceutical relevance.

Transferability must be examined below the host-family label. Multi-omics comparison of CHO parental hosts has revealed cell-line-specific differences in bioprocessing traits [25]. An intervention or model developed in one background cannot be assumed to transfer unchanged. The claim should identify expected invariants and variables

requiring re-estimation. External testing should also examine whether uncertainty remains calibrated, because apparently accurate point predictions can still support unsafe decisions when confidence is overstated.

Experimental validation requires orthogonal evidence. Cellular measurements should confirm the intended state; process measurements should define context; molecular analytics should assess product attributes; functional assays should test activity; and longitudinal perturbations should evaluate stability and robustness. Computational representations should be tested prospectively rather than judged only by retrospective fit [20].

Transferability should be stated as an envelope rather than a binary property. Relevant dimensions include host, parental background, construct, product format, medium, operating mode, duration, measurement system, scale, and decision use. Recalibration may suffice when parameters differ; re-specification is required when the mechanism changes [26]. A transferable architecture should consequently preserve the meaning of its states and decision boundaries even when the specific measurements, model parameters, or engineering actions differ across platforms.

Limitations and research agenda

The architecture is principally organized around living mammalian systems for therapeutic-protein production. HEK293 cells illustrate that alternative mammalian hosts possess distinct expression, modification, safety, and process characteristics [28]. The architecture may be adapted, but its state definitions, quality attributes, secretory constraints, and validation endpoints cannot be transferred automatically. Adaptation should begin by identifying which relationships are genuinely shared and which depend on host-specific biology, product class, or manufacturing purpose.

Cell-free gene expression marks a deeper boundary. Cell-free systems remove living-cell growth, genomic drift, clonal evolution, and some regulatory layers while introducing a different architecture of resource supply, energy regeneration, reaction stability, folding, modification, and scale [29]. Transfer therefore requires redefinition of mechanisms and observables. Similar terminology should not obscure the fact that resource limitation, quality formation, instability, and robustness can have fundamentally different causal structures in living-cell and cell-free production systems.

A central research priority is to test whether the architecture yields predictions more transferable and pharmaceutically informative than productivity-centered models. Required studies include causal perturbations, longitudinal single-cell analysis, product-diverse secretory comparisons, and prospective disturbance testing. The multicausal nature of CHO instability requires comparison of genomic, epigenetic, physiological, and selective explanations [22].

Figure 2 presents the original conceptual synthesis for trade-off space among yield, quality, function, and robustness, showing how the article's principal components, evidence relationships, uncertainties, and decision boundaries are connected.



Figure 2. Trade-Off Space among Yield, Quality, Function, and Robustness

The trade-off space is a hypothesis, not a measured design space. Objectives may improve together in some regions and diverge in others, depending on the active constraint and acceptance conditions. Future work should test whether a robust feasible region can be identified prospectively and whether it remains stable after changes in host, product, operating mode, duration, or scale. Such work should report failed transfers and boundary violations as informative results rather than treating them only as optimization setbacks.

CONCLUSION

The Therapeutic Cell-Factory Reconciliation Architecture reframes biomanufacturing as a coupled, product-centered system in which host state, resource allocation, secretory processing, process history, product attributes, stability, measurement, and intervention must be evaluated together. Its principal contribution is the treatment of yield, molecular quality, biological function, and manufacturing robustness as non-substitutable objectives whose relationships change with host, molecule, culture phase, process mode, and active constraint. The framework distinguishes direct evidence from proxy measurement, association from causation, model output from pharmaceutical consequence, and conceptual portability from validated transfer. It remains an original non-empirical synthesis rather than a universal design, validated world model, qualified control strategy, clinical recommendation, regulatory determination, or deployment-ready manufacturing system. Its value lies in making assumptions, dependencies, and validation obligations explicit before cell-factory performance is translated into manufacturing or product claims.

ACKNOWLEDGMENTS: None

CONFLICT OF INTEREST: None

FINANCIAL SUPPORT: None

ETHICS STATEMENT: None

REFERENCES

1. Walsh G, Walsh E. Biopharmaceutical benchmarks 2022. Nat Biotechnol. 2022;40(12):1722-60. doi:10.1038/s41587-022-01582-x
2. O'Brien SA, Hu WS. Cell culture bioprocessing—the road taken and the path forward. Curr Opin Chem Eng. 2020;30:100663. doi:10.1016/j.coche.2020.100663
3. Hong JK, Lakshmanan M, Goudar C, Lee DY. Towards next generation CHO cell line development and engineering by systems approaches. Curr Opin Chem Eng. 2018;22:1-10. doi:10.1016/j.coche.2018.08.002
4. Ha TK, Kim D, Kim CL, Grav LM, Lee GM. Factors affecting the quality of therapeutic proteins in recombinant Chinese hamster ovary cell culture. Biotechnol Adv. 2022;54:107831. doi:10.1016/j.biotechadv.2021.107831
5. Lee AP, Kok YJ, Lakshmanan M, Leong D, Zheng L, Lim HL, et al. Multi-omics profiling of a CHO cell culture system unravels the effect of culture pH on cell growth, antibody titer, and product quality. Biotechnol Bioeng. 2021;118(11):4305-16. doi:10.1002/bit.27899
6. Donaldson JS, Dale MP, Rosser SJ. Decoupling growth and protein production in CHO cells: A targeted approach. Front Bioeng Biotechnol. 2021;9:658325. doi:10.3389/fbioe.2021.658325
7. Zeh N, Schmidt M, Schulz P, Fischer S. The new frontier in CHO cell line development: From random to targeted transgene integration technologies. Biotechnol Adv. 2024;75:108402. doi:10.1016/j.biotechadv.2024.108402
8. Donaldson J, Kleinjan DJ, Rosser S. Synthetic biology approaches for dynamic CHO cell engineering. Curr Opin Biotechnol. 2022;78:102806. doi:10.1016/j.copbio.2022.102806
9. Jerabek T, Keysberg C, Otte K. The potential of emerging sub-omics technologies for CHO cell engineering. Biotechnol Adv. 2022;59:107978. doi:10.1016/j.biotechadv.2022.107978
10. Mulukutla BC, Mitchell J, Geoffroy P, Harrington C, Krishnan M, Kalomeris T, et al. Metabolic engineering of Chinese hamster ovary cells towards reduced biosynthesis and accumulation of novel growth inhibitors in fed-batch cultures. Metab Eng. 2019;54:54-68. doi:10.1016/j.ymben.2019.03.001

11. Chen Y, Liu X, Anderson JYL, Naik HM, Dhara VG, Chen X, et al. A genome-scale nutrient minimization forecast algorithm for controlling essential amino acid levels in CHO cell cultures. Biotechnol Bioeng. 2022;119(2):435-51. doi:10.1002/bit.27994
12. Gutierrez JM, Feizi A, Li S, Kallehauge TB, Hefzi H, Grav LM, et al. Genome-scale reconstructions of the mammalian secretory pathway predict metabolic costs and limitations of protein secretion. Nat Commun. 2020;11(1):68. doi:10.1038/s41467-019-13867-y
13. Pieper LA, Strotbek M, Wenger T, Gamer M, Olayioye MA, Hausser A. Secretory pathway optimization of CHO producer cells by co-engineering of the mitosRNA-1978 target genes CerS2 and Tbc1D20. Metab Eng. 2017;40:69-79. doi:10.1016/j.ymben.2017.01.003
14. Budge JD, Knight TJ, Povey J, Roobol J, Brown IR, Singh G, et al. Engineering of Chinese hamster ovary cell lipid metabolism results in an expanded ER and enhanced recombinant biotherapeutic protein production. Metab Eng. 2020;57:203-16. doi:10.1016/j.ymben.2019.11.007
15. Malm M, Kuo CC, Moradi Barzadd M, Mebrahtu A, Wistbacka N, Razavi R, et al. Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins. Metab Eng. 2022;72:171-87. doi:10.1016/j.ymben.2022.03.009
16. Sumit M, Dolatshahi S, Chu AHA, Cote K, Scarcelli JJ, Marshall JK, et al. Dissecting N-glycosylation dynamics in Chinese hamster ovary cells fed-batch cultures using time course omics analyses. iScience. 2019;12:102-20. doi:10.1016/j.isci.2019.01.006
17. Dovgan T, Golghalyani V, Zurlo F, Hatton D, Lindo V, Turner R, et al. Targeted CHO cell engineering approaches can reduce HCP-related enzymatic degradation and improve mAb product quality. Biotechnol Bioeng. 2021;118(10):3821-31. doi:10.1002/bit.27857
18. Rogstad S, Yan H, Wang X, Powers D, Brorson K, Damdinsuren B, et al. Multi-attribute method for quality control of therapeutic proteins. Anal Chem. 2019;91(22):14170-7. doi:10.1021/acs.analchem.9b03808
19. Baik JY, Lee KH. A framework to quantify karyotype variation associated with CHO cell line instability at a single-cell level. Biotechnol Bioeng. 2017;114(5):1045-53. doi:10.1002/bit.26231
20. Smiatek J, Jung A, Bluhmki E. Towards a digital bioprocess replica: Computational approaches in biopharmaceutical development and manufacturing. Trends Biotechnol. 2020;38(10):1141-53. doi:10.1016/j.tibtech.2020.05.008
21. Tzani I, Herrmann N, Carillo S, Spargo CA, Hagan R, Barron N, et al. Tracing production instability in a clonally derived CHO cell line using single-cell transcriptomics. Biotechnol Bioeng. 2021;118(5):2016-30. doi:10.1002/bit.27715
22. Dahodwala H, Lee KH. The fickle CHO: A review of the causes, implications, and potential alleviation of the CHO cell line instability problem. Curr Opin Biotechnol. 2019;60:128-37. doi:10.1016/j.copbio.2019.01.011
23. Becker L, Sturm J, Eiden F, Holtmann D. Analyzing and understanding the robustness of bioprocesses. Trends Biotechnol. 2023;41(8):1013-26. doi:10.1016/j.tibtech.2023.03.002
24. MacDonald MA, Nöbel M, Roche Recinos D, Martínez VS, Schulz BL, Howard CB, et al. Perfusion culture of Chinese hamster ovary cells for bioprocessing applications. Crit Rev Biotechnol. 2022;42(7):1099-115. doi:10.1080/07388551.2021.1998821
25. Lakshmanan M, Kok YJ, Lee AP, Kyriakopoulos S, Lim HL, Teo G, et al. Multi-omics profiling of CHO parental hosts reveals cell line-specific variations in bioprocessing traits. Biotechnol Bioeng. 2019;116(9):2117-29. doi:10.1002/bit.27014
26. Park SY, Kim SJ, Park CH, Kim J, Lee DY. Data-driven prediction models for forecasting multistep ahead profiles of mammalian cell culture toward bioprocess digital twins. Biotechnol Bioeng. 2023;120(9):2494-508. doi:10.1002/bit.28405
27. Park SY, Choi DH, Song J, Lakshmanan M, Richelle A, Yoon S, et al. Driving towards digital biomanufacturing by CHO genome-scale models. Trends Biotechnol. 2024;42(9):1192-203. doi:10.1016/j.tibtech.2024.03.001
28. Tan E, Chin CSH, Lim ZFS, Ng SK. HEK293 cell line as a platform to produce recombinant proteins and viral vectors. Front Bioeng Biotechnol. 2021;9:796991. doi:10.3389/fbioe.2021.796991
29. Silverman AD, Karim AS, Jewett MC. Cell-free gene expression: An expanded repertoire of applications. Nat Rev Genet. 2020;21(3):151-70. doi:10.1038/s41576-019-0186-3